A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma.
Shanshan ZhangZhaojian GongPeter O OladimejiDuane G CurrierQipan DengMing LiuTaosheng ChenYong LiPublished in: Experimental hematology & oncology (2019)
Our findings suggest that histone deacetylase inhibitors are potent therapeutic agents against medulloblastoma.